RxDoctor Payments Data

Craig Moss, MD

Internal Medicine · Kingston, NYNPI 1568414126

Payments from drug & device makers

$7,825in general payments, 2019–2025

Across 432 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$903
  • AbbVie$861
  • Novo Nordisk$689
  • AstraZeneca$653
  • GSK$601
  • Merck$444
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$7,798100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)43$903
AbbVie(2 entities)49$861
Novo Nordisk33$689
AstraZeneca43$653
GSK31$601
Merck28$444
Johnson & Johnson(2 entities)20$390
Novartis25$383
Lilly USA, LLC21$332
Pfizer15$293
Bayer15$278
Viiv Healthcare Company9$185
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$173
Exact Sciences6$137
E.r. Squibb & Sons, L.L.C.6$115
Dexcom, Inc.5$95
Amarin Pharma, Inc.5$73
Gilead4$65
Fresenius Kabi USA, LLC3$59
Otsuka America Pharmaceutical, Inc.3$57
Sanofi-aventis U.S. LLC2$55
Tetraphase Pharmaceuticals, Inc.3$55
Abbott3$49
Amneal Pharmaceuticals LLC2$47
Seqirus USA Inc2$40
Inspire Medical Systems, Inc.2$38
Takeda Pharmaceuticals U.S.A., Inc.2$37
Avanir Pharmaceuticals, Inc.2$36
Recordati_rare_diseases_inc.2$35
Regeneron Healthcare Solutions, Inc.2$33
Sunovion Pharmaceuticals Inc.2$31
Radius Health, Inc.1$30
Boehringer Ingelheim2$29
Endo Pharmaceuticals Inc.2$29
IBSA Pharma Inc.2$28
Hologic Sales And Service, LLC2$28
Kyowa Kirin, Inc.1$26
Sandoz1$25
Harmony Biosciences LLC1$24
Bardy Diagnostics, Inc.1$23
Sumitomo Pharma America, Inc.1$23
Kiniksa Pharmaceuticals, Ltd.1$20
UCB, Inc.1$20
Paratek Pharmaceuticals, Inc.1$20
Mylan Specialty L.p.1$20
Esperion Therapeutics, Inc.1$19
Eisai Inc.1$19
Endo USA, Inc.1$18
Sobi, Inc1$17
Baxter Healthcare1$15
Circassia Inc.1$15
Astellas Pharma US Inc1$15
Theratechnologies Inc.1$15
Teva Pharmaceuticals USA, Inc.1$15
VBI Vaccine (delaware) Inc.1$14
Verona Pharma, Inc.1$14
Philips North America LLC1$14
Medtronic1$14
Kowa Pharmaceuticals America, Inc.1$12
Antares Pharma, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,825 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$220,363
Medicare patients
395
Services billed
2,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$171,187
EnbrelEtanercept11$80,265
EliquisApixaban82$73,847
XareltoRivaroxaban70$68,185
JardianceEmpagliflozin51$55,643
FarxigaDapagliflozin Propanediol53$45,716
MounjaroTirzepatide31$44,565
Teriparatide23$42,776
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$41,600
TrulicityDulaglutide14$24,051
Breo ElliptaFluticasone/Vilanterol35$20,749
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$12,516
MyrbetriqMirabegron15$10,262
Rosuvastatin Calcium401$9,826
Candesartan Cilexetil79$6,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$689$171,187109 claims
AmgenEnbrel$903$80,26511 claims
PfizerEliquis$293$73,84782 claims
Lilly USA, LLCMounjaro, Trulicity$332$68,61645 claims
Johnson & JohnsonXarelto$390$68,18570 claims
GSKTrelegy Ellipta, Breo Ellipta$601$62,34999 claims
Boehringer IngelheimJardiance$29$55,64351 claims
AstraZenecaFarxiga, Symbicort$653$49,97165 claims
Astellas Pharma US IncMyrbetriq$15$10,26215 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$47$5,537226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →